Lantern Pharma Inc. (LTRN)
| Market Cap | 7.70M -82.2% |
| Revenue (ttm) | n/a |
| Net Income | -18.65M |
| EPS | -1.63 |
| Shares Out | 12.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,316 |
| Open | 0.6683 |
| Previous Close | 0.6400 |
| Day's Range | 0.5806 - 0.6770 |
| 52-Week Range | 0.5806 - 4.3400 |
| Beta | 2.46 |
| Analysts | Strong Buy |
| Price Target | 17.50 (+2,805.53%) |
| Est. Earnings | Nov 16, 2026 |
About LTRN
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LTRN stock is "Strong Buy." The 12-month stock price target is $17.5, which is an increase of 2,805.53% from the latest price.
News
Lantern Pharma Proxy statement: Proxy filing
Lantern Pharma filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Lantern Pharma Transcript: The ThinkEquity Conference
The presentation highlighted a six-path clinical portfolio, biomarker-led drug development, and plans to spin out Open-Medicine AI beyond oncology. Near-term priorities include LP-300 data, new trial launches, regional licensing, and AI financing.
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026.
Lantern Pharma Proxy statement: Proxy filing
Lantern Pharma filed a proxy statement on October 8, 2026, providing details for shareholder voting and corporate governance matters.
Lantern receives Taiwan approval to open next stage of Phase 2 HARMONIC trial
Lantern Pharma (LTRN) announced that it has received regulatory and IRB approvals in Taiwan to open the next stage of its Phase 2 HARMONIC trial of LP-300. The Taiwan Food…
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open...
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering.
Lantern Pharma prices 3.67M shares at $1.09 in registered direct offering
Lantern Pharma (LTRN) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 3,669,725 shares of its common stock at a purchase…
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”, the “Company” or “we”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop ...
Lantern Pharma Transcript: Investor update
Open Medicine reported more than 200 users, growing monthly, and hundreds of molecules generated by a handful of customers. Priorities include enterprise adoption, expansion into new disease areas and modalities, and a separate financing round.
Lantern Pharma Press release: Investor update
Lantern Pharma issued a press release on September 23, 2026, disclosing material business information to investors.
Lantern Pharma Slides: Investor update
Lantern Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 23, 2026.
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
DALLAS--(BUSINESS WIRE)--Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmark.
Lantern Pharma secures USPTO notice of allowance for LP-284 patent
Lantern Pharma (LTRN) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled “Method for Treating Blood Cancer...
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announc...
Lantern Pharma to host webinar on Open-Medicine AI
Lantern Pharma (LTRN) will host a live webinar on Wednesday, September 23 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI the…
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today...
Lantern Pharma reports Q2 EPS (57c) vs (40c) last year
Cash, cash equivalents, and marketable securities of approximately $7.4 million as of June 30, 2026. Funding received in the second quarter consisted of approximately $4.4 million in gross proceeds fr...
Lantern Pharma Earnings Call Transcript: Q2 2026
Clinical programs advanced with strong AI integration, including a new AI spin-out and multiple regulatory clearances. Operating expenses fell 25% year-over-year, but net loss rose due to non-cash warrant expenses. Open-Medicine AI is set for independent growth and capital raising.
Lantern Pharma Quarterly report: Q2 2026
Lantern Pharma has published its Q2 2026 quarterly earnings report on August 14, 2026.
Lantern Pharma Earnings release: Q2 2026
Lantern Pharma released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Lantern Pharma Slides: Q2 2026
Lantern Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 14, 2026.
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET.
Lantern Pharma establishes Open-Medicine AI as separate company
Lantern Pharma (LTRN) announced the formal creation of Open-Medicine AI and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which have received Lanter...